Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service antireflux & hiatal hernia surgery cases in Kansas: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 9% on average (180 state-years, 2020–2024): read it as a direction with a margin.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 3 | 310 | 20% |
| 2020 | 1 | 286 | 23% |
| 2021 | 4 | 313 |
Laparoscopic fundoplication and paraesophageal hernia repair. Professional codes (what the surgeon bills): CPT 43280, 43281, 43282; the hospital bills MS-DRG 326, 327, 328.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in Kansas; 4 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Hernia repair | 27 | 2,322−2.7%/yr | −2.7%/yr | 6.01.0× | 12% | 2,400 in 2030+0.5%/yr |
| Cholecystectomy & appendectomy |
Antireflux & hiatal hernia surgery in every state, and its device makers · Every procedure market in Kansas · Every state · Compare with Ohio
| ≈ 380 |
| – |
| 2026 est. | ≈ 390 | – |
| 28% |
| 2022 | 0 | 322 | 31% |
| 2023 | 2 | 297 | 34% |
| 2024 | 4 | 304 | 36% |
| 2025 from claims | – | 380 308–447 | 36% |
| 2026 forecast | – | 393 308–494 | 36% |
| 2027 forecast | – | 406 301–537 | 36% |
| 2028 forecast | – | 420 297–579 | 37% |
| 2029 forecast | – | 433 295–621 | 37% |
| 2030 forecast | – | 448 293–664 | 37% |
In 2025, 26% inpatient hospital, 74% hospital outpatient.
| Forecast, Medicare FFS | Inpatient | Hospital outpatient |
|---|---|---|
| 2026 · ~390 | ~100 | ~290 |
| 2027 · ~410 | ~100 | ~300 |
| 2028 · ~420 | ~110 | ~310 |
The forecast’s cases at the projected mix.
The mix is steady: the trend moves no setting by a point or more by 2028.
CMS rule changes ahead
From CMS’s OPPS/ASC final rules; the move measured on CMS’s claim summary, nationally, code by code. Medicare only, and not in the projected bars.
| +0.3%/yr |
| 1.3 |
| 0% |
| 810 in 2030+0.1%/yr |
| Illinois | 12 | 791−1.1%/yr | −1.1%/yr | 0.6 | 0% | 930 in 2030+2.8%/yr |
| Michigan | 3 | 585−8.8%/yr | −8.8%/yr | 0.7 | 0% | 540 in 2030−1.4%/yr |
| Indiana | 9 | 580−0.9%/yr | −0.9%/yr | 0.8 | 0% | 630 in 2030+1.3%/yr |
| Wisconsin | 6 | 452−0.5%/yr | −0.5%/yr | 0.8 | 0% | 590 in 2030+4.6%/yr |
| Minnesota | 3 | 341−4.9%/yr | −4.9%/yr | 0.8 | 0% | 500 in 2030+6.7%/yr |
| Nebraska | 5 | 255+2.2%/yr | +2.2%/yr | 1.0 | 0% | 370 in 2030+6.2%/yr |
| South Dakota | 6 | 218+2.8%/yr | +2.8%/yr | 1.7 | 0% | 300 in 2030+5.3%/yr |
| Iowa | 3 | 193−6.6%/yr | −6.6%/yr | 0.4 | 0% | 300 in 2030+7.6%/yr |
| 50 |
| 1,841−5.1%/yr |
| −5.1%/yr |
| 4.61.1× |
| 5% |
| 1,870 in 2030+0.2%/yr |
| Colorectal resection | 4 | 782−3.5%/yr | −3.5%/yr | 2.01.1× | 0% | 730 in 2030−1.1%/yr |
| Breast reconstruction | 0 | 213−7.1%/yr | −7.1%/yr | 0.51.3× | 39% | 160 in 2030−4.9%/yr |
| Bariatric surgery | 1 | 105−14%/yr | −14%/yr | 0.31.3× | 0% | 60 in 2030−7.8%/yr |
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
Johnson & Johnson MedTech leads with 100% of company spending on these surgeons in 2025, level with 2024.
In 2025, 1 company reported engagement with Kansas’s surgeons worth $236 in consulting, speaking, meals and travel tied to these products, about $59 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 5 clearances and approvals in the category.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.